SOURCE: Streetwise Reports

Streetwise Reports

April 09, 2015 09:20 ET

Arno Therapeutics Inc.'s CEO Alexander Zukiwski Interviewed by The Life Sciences Report

SAN FRANCISCO, CA--(Marketwired - Apr 9, 2015) - Cancers are generally treated by destruction of cancer cells. Infectious diseases are generally treated by destruction of invading pathogens. If infected host cells are viewed as viable biological targets, new paradigms for development of anti-infective agents become apparent. In this interview with The Life Sciences Report, Alexander Zukiwski MD, CEO and CMO of Arno Therapeutics Inc. (OTCQB: ARNI), describes how onapristone and AR-42 for cancers, and AR-12 as an anti-infective agent, are positioned to move through clinical trials and boost investors' portfolios.

The Life Sciences Report: Targeted cancer therapeutics are broadly defined. What advantages does Arno Therapeutics Inc.'s platform present compared to technologies such as antibody drug conjugates and combination therapeutics?

Alexander Zukiwski: I'll use our lead development compound, onapristone, as an example. Onapristone has several potential advantages. It has demonstrated preclinical activity against a number of different tumor types, including endometrial, prostate and breast cancers. It is an orally available small molecule, so patients would not have to go back and forth to a hospital or clinic to receive intravenous (IV) administrations or subcutaneous injections, as required for therapeutic antibodies or antibody-drug conjugates. Onapristone is well tolerated, with a manageable safety profile as demonstrated by our Phase 1 study, in which onapristone was administered for up to 40 weeks. This latter point is important, because patients with cancer usually have multiple comorbidities that often require treatment with additional therapeutics. Having a medication like onapristone, which is well tolerated and doesn't cause side effects such as nausea, vomiting or diarrhea, is very important…

Continue reading this interview with Alexander Zukiwski: Arno Therapeutics Seeks to Inhibit Cancer and Enhance Portfolios

About Streetwise Reports - The Life Sciences Report
Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that will help you capitalize on these developing trends.

DISCLOSURE:
Arno Therapeutics Inc. paid The Life Sciences Report to conduct, produce and distribute the interview. Alexander Zukiwski had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Alexander Zukiwski and not of The Life Sciences Report or its officers.

Contact Information

  • Contact Info:
    Brandon Fung
    Tel: 707-981-8107
    Email: Email Contact